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Abstract
Tetracycline-class antibiotics are frequently prescribed by dermatologists, commonly
for acne vulgaris. Gastrointestinal absorption of first and second-generation
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tetracycline-class antibiotics, including doxycycline and minocycline, may be reduced

4

by co-administration with food, resulting in potentially lower clinical efficacy. Devel-
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opment of novel compounds and formulations that are not impacted by diet could
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improve compliance, absorption, and effectiveness among patients. The objective of
this study is to investigate weight-based dosing protocols and the impact of food
intake, including high-fat meals, on the absorption, and clinical efficacy of sarecycline,
a novel oral narrow-spectrum third-generation tetracycline-class antibiotic approved
by the Food and Drug Administration for acne vulgaris treatment. Data from 12 clinical studies were analyzed using population pharmacokinetic modeling, exposure–
response modeling and pharmacodynamics to evaluate sarecycline dosing recommendations. The extent of exposure is estimated to decrease by 21.7% following coadministration of a sarecycline tablet with a high-fat meal. Based on the PopPK-PD
model, this is equivalent to a decrease in efficacy of 0.9 inflammatory lesions, which
is not clinically meaningful. Sarecycline can be administered using weight-based dosing with or without food. Co-administration with high-fat food has a limited impact
on clinical efficacy. The pharmacokinetics of oral sarecycline may provide added convenience and support ease of use and improved compliance for acne vulgaris
patients.
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I N T RO DU CT I O N

of a brand doxycycline 40 mg modified-release capsule after ingestion
with a 1000 calorie, high fat, high protein meal that included dairy

Tetracycline-class antibiotics are frequently prescribed by dermatolo-

products when compared to fasted conditions.20 The FDA-approved

1,2

gists, primarily for the treatment of acne vulgaris and rosacea.

prescribing information with this doxycycline modified-release formu-

Tetracycline-class antibiotics include tetracycline (first generation),

lation states that this decrease in systemic exposure may be clinically

doxycycline and minocycline (second generation), and sarecycline (third

significant with the recommendation that it be taken at least 1 h prior

generation).3,4 Prior to sarecycline, all tetracycline-class antibiotics

to or 2 h after meals.20

exhibited broad-spectrum activity against a wide range of aerobic and

Especially with immediate-release formulations, patients are com-

anaerobic Gram-positive and Gram-negative bacteria.3 This broad-

monly instructed to ingest doxycycline with food to reduce GI side

spectrum activity may induce bacterial resistance and disrupt the micro-

effects.18,21–23 and a large volume of liquid (water). Administration of

flora, leading to dysbiosis in the gastrointestinal (GI) and genitourinary

doxycycline taken without food and a large glass of water has been

(GU) tracts, which are associated with adverse events (AEs) such as diar-

associated with “pill esophagitis” which causes pain, and gastric side

rhea and vulvovaginal mycotic/candidiasis infections.5–8 In addition, pro-

effects such as nausea and vomiting.19,21,22 Likewise, ingestion of

longed use of broad-spectrum antibiotics such as doxycycline has been

food along with minocycline is reported to help reduce the risk of

associated with an increased risk of inflammatory bowel disease9–11

esophageal irritation and ulceration.18 Lastly, oral tetracycline is cur-

Sarecycline is an immediate-release tetracycline derivative,
designed with a stable structural modification at hydrocarbon C7, to

rently suggested to be given 1–2 h before meals to reduce potential
impact of food on GI absorption.24

produce a narrow spectrum antibiotic profile inclusive of activity

Currently, sarecycline has been Food and Drug Administration

against Cutibacterium acnes.3 The structural modifications incorpo-

(FDA)-approved specifically for the treatment of moderate-to-severe

rated result in direct binding to the bacterial mRNA within the bacte-

acne vulgaris in patients 9 years of age and older, and can be taken

rial ribosome 30S subunit and a low propensity to induce antibiotic

once daily with or without food.25 The recommended dosage of sar-

resistance.

3,12,13

The rationale for an immediate-release formulation

ecycline is based on body weight and is available in three daily dos-

of sarecycline is supported by minimal GI-associated AEs noted in

ages (60, 100, and 150 mg)24 (Table 1). Previous clinical and non-

3,12–15

clinical studies.

Sarecycline has demonstrated activity against

clinical studies of sarecycline pharmacokinetics (PK) suggest that it

clinically relevant Gram-positive bacteria, and reduced activity against

may be administered with or without food, which supports this rec-

Gram-negative bacteria commonly found in the GI tract, with a low

ommendation in the approved product labeling.25–27 The data evalua-

rates of AEs reported in pivotal phase 2 and phase 3 clinical trials and

tion below reports integrative PK/pharmacodynamics (PD) analyses

3,14,15

in an 40-week safety extension study.

Oral antibiotics may vary in their bioavailability depending on sev-

evaluating both the relevance of weight-based dosing and the impact
of food intake on the efficacy of sarecycline.

eral factors including intra-individual weight-to-dose ratio and potential food-drug interactions. The existing tetracyclines-class antibiotics,
tetracycline, doxycycline and minocycline, are structurally bound by

2

METHODS

|

diets and medications that are high in divalent and trivalent metal ions
such as calcium, magnesium, iron, and aluminum, which can reduce GI

2.1

|

Data and software

absorption of the antibiotics; iron has been shown to markedly reduce
GI absorption of doxycycline and minocycline.16–19 In addition, inges-

Population pharmacokinetic (PPK) modeling and exposure–response

tion with a high-fat meal may reduce doxycycline GI absorption. Fol-

(E-R) modeling were utilized to support dosing recommendations. The

lowing single dose administration of enteric-coated delayed release
150-mg doxycycline tablet, the mean maximum plasma concentration
(Cmax) was 19% lower with a high fat meal, including milk, compared
to fasted conditions.19 The effect from food can vary based on the
dose (less effect at higher doses). However, the clinical impact has not
been studied. Additionally, a decrease in the rate (Cmax) and extent
(area-under-the curve [AUC]) of GI absorption of 45% and 22%,
respectively, were reported in human subjects given a single oral dose

TABLE 1

Recommended weight-based dosing for sarecycline

Body weight (kg)

Tablet strength (mg)

33–54

60

55–84

100

85–136

150
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analysis was carried out using NONMEM (Version 7.3, ICON Develop-

2.2

|

Population pharmacokinetic modeling

ment Solutions) on workstations with Intel® Core™ i7 processors, Windows 7 Professional and the GNU gfortran compiler (Version 4.5.0,

The structural pharmacokinetic (PK) model was initially developed based

http://ftp.globomaxnm.com/Public/nonmem7/compilers).

Post-

on phase 1 data with capsule and tablet formulations and was character-

processing of NONMEM analysis results was carried out in R version

ized using nonlinear mixed effects modeling. In brief, PPK modeling

3.2.2. The stepwise covariate modeling (SCM) was carried out using Perl-

included estimated concentration time profiles at the patient level and

speaks-Nonmem (PsN), version 4.2.0. Model development was carried

provided for quantitative understanding of sarecycline plasma concen-

out using first order conditional estimation with Interaction (FOCE-I).

trations in fed/fasted states and according to body weight and gender.

Initial development of PK/PD models was based on single- and

In the current analysis, PK data from subjects in two phase 3 pivotal

multiple dose data inclusive of results in 144 healthy subjects.

studies were used to refine the structural PK model and included tablet

These patients were obtained from 12 clinical studies (Table 2).

formulations. The prediction corrected visual predictive check (VPC)

These PK/PD models were utilized to guide phase 3 study design.

normalizes observations and predictions from different dose groups to

Upon completion of phase 3 studies, the PK/PD models were

assess model fitness when not stratifying by dose (Figure 1). The central

expanded to include the phase 3 study data with the results

tendency of the data and variability are well-described by the model.

reported here.

The parameters of the final PK model are found in Table S1.

TABLE 2

Summary of data included in population pharmacokinetic analysis

Study

Study design

Study population

N

Na

Treatment

PR-10711

Food effect of capsules

Healthy males
and females

16

16

240 mg capsule, fasted or
following high fat meal

PR-01010

Placebo-controlled single dose
study

Healthy males

64

48

20–480 mg capsules, fasted

PR-05011

Placebo-controlled multiple dose
study

Healthy males

56

42

40–320 mg QD for 7 days,
capsules, fasted

PR-07112

Thorough QT/QTc study

Healthy males
and females

48

41

500 mg capsule, fasted

PR-11914

Food effect and bioavailability for
tablet formulation

Healthy males
and females

19

19

150 mg tablet versus aqueous
solution, fasted versus high-fat
meal

PR-12014

Relative bioavailability of tablet
and capsule formulations

Healthy males
and females

26

26

100 mg capsule versus tablet,
fasted

SRC-PK-03

Hepatic impairment study: ChildPugh A, B versus normal
(8/group)

Healthy males
and females

24

24

150 mg tablet, light meal 1–2 h
predose

SRC-PK-04

Renal impairment study: Mild,
moderate, or severe renal
impairment versus normal
(8/group)

Healthy males
and females

32

32

150 mg tablet, light meal 1–2 h
predose

SRC-PK-06

Multiple dose pharmacokinetic
study of tablet formulation at
three dose levels

Healthy males
and females

24

24

60, 100, and 150 mg tablet QD,
fasted for 7 days

SRC-PK-08

Drug–drug interaction to examine
effect of sarecycline on oral
contraceptive exposure

Healthy females

26

26

Oral contraceptive QD for
24 days + sarecycline 150 mg
tablet QD, fasted

PR-10411

Phase 2 study

Subjects with
facial acne
vulgaris

285

212

Placebo versus sarecycline
capsules, 0.75, 1.5, or 3.0 mg/kg
QDb

SC1401, SC1402

Phase 3 study

Subjects with
facial acne
vulgaris

~1000 each

~500 each

Placebo versus sarecycline, 1.5
tablet mg/kg QDc

Abbreviations: QD, once a day; mg, milligram.
a
Subjects treated with sarecycline.
b
Subjects received the same dose regardless of weight (50, 100, or 200 mg); weight range limited to 52–88 kg.
c
1.5 mg/kg corresponds to 60 mg tablet for subjects who weighed 33–54 kg, 100 mg tablet for subjects who weighed 55–84 kg, and 150 mg tablets for
subjects who weighed 85–136 kg.
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F I G U R E 1 Visual predictive check for PK model stratified by body weight. Circles represent observations. Solid blue line represents median of
the observed sarecycline concentrations. Dashed lines represented 2.5th and 97.5th percentiles of the observed sarecycline concentrations. Shaded
areas represent the 95% confidence interval around the prediction-corrected median (green area), and the 2.5th and 97.5th percentile of the
simulated concentrations (gray areas). All observations and predictions are adjusted using prediction correction as described in Bergstrand et al.23

F I G U R E 2 Visual predictive check of inflammatory lesion counts with the E-R model. Circles represent observed concentrations. Solid black
line represents median of the observed sarecycline concentrations. Dashed lines represented 2.5th and 97.5th percentiles of the observed
concentrations. Shaded areas represent the 95% confidence interval around the prediction-corrected median (green area), and the 2.5th and
97.5th percentile of the simulated concentrations (gray areas). All observations and predictions are adjusted using prediction correction as
described in Bergstrand et al.28

2.3

|

Exposure–response modeling

lesion counts at Week 12 and a dichotomized Investigator's Global
Assessment (IGA) score (either “success,” denoted as ≥2-point

The co-primary endpoints in the phase 2 and the phase 3 studies

decrease from baseline in the IGA assessment and a score of clear

were the absolute change from baseline in the facial inflammatory

[0] or almost clear [1], or “failure”) at Week 12. The E-R model for
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inflammatory lesion count was a longitudinal model composed of pla-

Additionally, for drug effect, indirect response models were consid-

cebo, time, baseline count, and drug effects. The “drug effect” portion

ered to account for time delay between sarecycline exposure and the

quantified the relationship between different levels of exposure (area

associated observation of the endpoint. The E-R analysis evaluated

under the concentration-time curve [AUC]) to differences in efficacy.

metrics of exposure (AUC at steady state [AUCss]) and other subject

T A B L E 3 Summary of model
predicted AUCss and Cmax.ss at midpoint
of each weight category using uniform
body weight distribution

Dose regimen (mg)

Body weight (kg)

Dose (mg)

AUCss (mg h/L)

Cmax,ss (mg/L)

60, 100, and 150

43

60

17.2

1.31

60, 100, and 150

70

100

24.6

1.65

60, 100, and 150

110

150

31.7

1.95

43

100

28.3

2.09

100
100

70

100

24.6

1.65

100

110

100

21.5

1.34

Abbreviations: AUCss, area under the concentration versus time curve at steady state; Cmax.ss, maximum
concentration at steady state.

F I G U R E 3 Model predicted AUCss using a uniform body weight distribution, by body weight category. (A) Body weight adjusted dose
regimen as in Phase 3 (60 mg, 100 mg, and 150 mg). (B) No dose adjustments by body weight (100 mg). Horizontal dotted lines are the mean
population AUCss prediction in a male with a body weight of 78.7 kg
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characteristics, including gender, weight and age to inflammatory

3

RE SU LT S

|

lesions counts and IGA. Individual sarecycline AUCss was derived
using the PPK model. The VPC for inflammatory lesion counts shows

3.1

|

Weight-based dosing

that overall, the model reasonably predicts the inflammatory lesion
counts versus time profile, although there is an over-prediction trend

A total of 562 subjects from 12 clinical studies (Table 2) were included

of decrease in inflammatory lesion counts at later time-points

in the PPK modeling. To note, subjects in phase 1 studies were

throughout all dose levels, including with placebo (Figure 2).

healthy

volunteers.

PPK

modeling

was

developed

using

a

2-compartment model with first order absorption with a lag time and
linear elimination (form the initial nonlinear mixed effects modeling).

2.4

|

Simulations

Weight effect was modeled by allometric scaling and with exponents
estimates. Apparent clearance unadjusted for bioavailability (CL/F)

Using the final PPK model, a simulation of the PK model was made

was estimated to 3.15 L/h (relative standard error [RSE]: 2.11%), V1/F

using a uniform weight distribution to illustrate the impact of weight

and apparent peripheral volume of distribution (V2/F) were estimated

and dosing regimens without assuming any distribution of weight.

to 54.2 L (RSE: 2.63%) and 15.1 L (RSE: 6.48%), respectively and ka

Both the phase 3 dose regimen (weight-based dosing wherein

was estimated to 3.45 h

60, 100, or 150 mg once daily was given for subjects who weighed

predictors of both F and ka. The exponent of the normalized weight

1

(RSE: 16.0%). Prandial state and dose were

33–54, 55–84, or 85–136 kg, respectively) and a 100 mg dose regi-

effect (CL/FWT) was estimated at 0.291. This simulation demonstrated

men to all were simulated.

that adjustment of dosing by body weight leads to similar differences

F I G U R E 4 Model predicted Cmax,ss using a uniform body weight distribution, by body weight category. (A) Body weight adjusted dose
regimen as in Phase 3 (60 mg, 100 mg, and 150 mg). (B) No dose adjustments by body weight (100 mg). Horizontal dotted lines are the mean
population Cmax,ss prediction in a male with a body weight of 78.7 kg
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in peak drug levels across weight groups compared with a 100 mg

4

|

DI SCU SSION

dose regimen (Table 3, Figures 3, 4).
The results of the current PK studies demonstrate that sarecycline
can be administered using a weight-based dosing regimen and can be

3.2 | Limited impact of food on sarecycline
efficacy

taken with or without food without a clinical relevant impact on efficacy. As described above, data with older first- and second-generation
tetracycline-class antibiotics report diet-related effects, which may

The E-R model examined inflammatory lesion counts with time, drug

potentially have impact on efficacy in some patients. Co-

exposure, and placebo effects and other subject characteristics

administration of a delayed-release doxycycline formulation with a

accounted for. Inflammatory lesion counts over 12 weeks was con-

high-fat meal reduced the overall bioavailability (AUC) by 15%–18%

sidered a continuous variable and was assessed using an indirect

compared to a fasted state, with published reports stating reduction

response model with the drug effect included on the production of

in doxycycline bioavailability by 26% and tetracycline bioavailability by

lesion counts. In addition, the relationship between IGA response

46%.23,29 Given that patients who take doxycycline are commonly

and sarecycline exposure (AUCss) and other subject characteristics

instructed to ingest the drug with food (including dairy products) to pre-

were evaluated using logistic regression methods. A combined simu-

vent GI tract-associated AEs, it is difficult to assess the true clinical impact

lation of PK and E-R models indicates support for administration of

of this decrease in bioavailability, especially when lower doses are pre-

sarecycline regardless of food intake. The exposure efficacy relation-

scribed. Similarly, coadministration of minocycline with iron or food

ship was relatively flat over the range of concentrations seen in

decreases its bioavailability by 77% and 13%–14%, respectively.29,30

phase 3 subjects (Table 3, Figure 3A). Co-administration of sar-

By contrast, PK/PD studies, coupled with PPK and E-R model

ecycline with a high-fat meal was estimated to result in a 21.7%

analyses, support that sarecycline is efficacious regardless of whether

reduction in exposure at steady state (AUCss) and a reduced

it is taken with or without food. In the current E-R model, co-

response of 0.9 inflammatory lesions (5.1 and 6.0 placebo adjusted

administration of sarecycline with a high-fat meal did not elicit a sig-

change in lesion counts, respectively); this lesion count reduction is

nificant change in exposure or in clinically meaningful effects on

not clinically relevant (Figure 5).

inflammatory lesion counts, with a negligible inflammatory lesion
decrease of 0.9 lesions. Additionally, analysis of simulation data of the
PK model supports weight-based dosing.
Based

on

bioavailbility

clinical

study

(PR-11914),

co-

administration with a high-fat (approximately 50% of total caloric content of the meal), high-calorie (800–1000 kcal) meal that included milk
produced a delay of Tmax by 0.53 h, and decreases in Cmax and AUC
by 31% and 27%, respectively; these results deemed not to be clinically relevant.25,27 Sarecycline is rapidly absorbed with a median time
peak plasma concentration (Tmax) of 1.5–2 h and there are no significant differences in PK of sarecycline based on age, weight, gender,
renal impairment, or mild to moderate hepatic impairment (Child Pugh
A or B).26 Sarecycline bioavailability has not been evaluated in endstage renal disease or severe hepatic impairment (Child-Pugh C). It is
important to note that although the effect of food on sarecycline PK
is comparable to doxycycline, the impact on sarecycline clinical efficacy, as shown in this study, was not clinically meaningful. No data
exist for other tetracycline-class drugs.
Weight-based dosing allows for similar differences in plasma sarecycline concentration across weight groups when compared with a
100 mg dose regimen. Taken together, thorough analyses of data on
weight-based dosing and the efficacy of sarecycline in both fed and
F I G U R E 5 Model predicted typical inflammatory lesion counts
exposure-response plot. Gray area is 50% prediction interval of
sarecycline AUCss in the phase 3 studies. Green area is 95% CI for the
typical E-R at 12 weeks. Vertical black line is median predicted
exposure in Phase 3. Vertical blue line is median predicted exposure
when sarecycline is administered with food. The net impacts on
efficacy were not clinically significant and do not necessitate dose
adjustments

non-fed states support recommendations in the FDA-approved product labeling stating that oral sarecycline may be administered once
daily with or without food, and dosed based on patient weight.
Approval by the FDA for use in patients 9 years of age and older and
data from pivotal phase 3 studies in patients with moderate to severe
inflammatory acne vulgaris support the therapeutic and safety benefits of oral sarecycline in many patients.25 Given the additional benefit

8 of 9

GRADA ET AL.

that sarecycline is administered daily with or without food, the convenience provided for the patient and the clinician are both highly
favorable.
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